Trial Number
551-25
Condition
Lung Cancer
Participant Age Range
18 years and older
Participant Gender
Any
Enrolling Participants
Yes
Overview
“A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs”
This study tests KB707, a new treatment for adults with advanced lung tumors, using a modified virus to boost the immune response against cancer.
It targets patients who haven't responded to or cannot tolerate standard treatments. KB707 will be given by nebulization, initially once a week, then every three weeks, or every two weeks in combination with Keytruda. Treatment will continue as long as it remains effective and safe.